• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Rimidi and ARKRAY Partner to Bring Glucose Data to the EHR

by Fred Pennic 05/09/2022 Leave a Comment

Rimidi and ARKRAY Partner to Bring Glucose Data to the EHR

What You Should Know:

– In an effort to make blood glucose data more actionable for providers and patients alike, Rimidi, a leading clinical management platform announced its integration with the ARKRAY GLUCOCARD® Shine Connex Blood Glucose Monitoring System to Rimidi’s Platform.

– The integration enables providers to manage blood-glucose control more proactively within existing workflows, thus boosting patient adherence.


Blood Glucose Data Directly Embedded in EHR

Diabetes is the most expensive chronic condition in the nation, with more than $237 billion spent each year on direct medical costs, and another $90 billion on reduced productivity. With over 37 million people in the U.S. currently living with the condition, patients must have access to reliable and affordable blood glucose monitoring systems. The integration between Rimidi and ARKRAY enables providers to see blood glucose data in their EHR existing workflows, thus providing a more comprehensive view of patients’ health, and in turn driving better clinical decisions. For example, providers are alerted when a patient has an out-of-range reading or has not taken their blood-glucose in a certain amount of time, prompting them to follow up with their patient accordingly.

“With a large portion of the U.S. population living with diabetes, and a significant amount living in areas with poor cellular service, patients need devices that they can rely on to monitor their conditions without having to schedule an in-person appointment with their provider,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “Through our partnership with ARKRAY, we’re tackling these challenges head on, ensuring more patients and providers have the tools they need to properly monitor conditions and make actionable insights that improve health outcomes.”

Tagged With: Blood Glucose Monitor, Continuous Glucose Monitoring (CGM), diabetes, Diabetes Management Platform, glucose data, MD, Patient Adherence, PhD, Rimidi

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |